VYNE Therapeutics (NASDAQ:VYNE) Trading Down 0.5%

Shares of VYNE Therapeutics Inc. (NASDAQ:VYNEGet Free Report) traded down 0.5% during mid-day trading on Thursday . The stock traded as low as $4.04 and last traded at $4.39. 11,252 shares were traded during mid-day trading, a decline of 96% from the average session volume of 298,540 shares. The stock had previously closed at $4.41.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Cantor Fitzgerald raised their target price on shares of VYNE Therapeutics from $5.00 to $9.00 in a research note on Friday, May 12th. HC Wainwright reissued a “buy” rating and set a $28.00 price objective on shares of VYNE Therapeutics in a research note on Monday, August 14th.

Read Our Latest Report on VYNE

VYNE Therapeutics Price Performance

The firm has a market capitalization of $14.40 million, a PE ratio of -0.40 and a beta of 1.50. The company has a 50-day moving average price of $4.51 and a 200-day moving average price of $4.54.

VYNE Therapeutics (NASDAQ:VYNEGet Free Report) last released its earnings results on Monday, August 14th. The company reported ($3.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.99) by ($1.09). VYNE Therapeutics had a negative net margin of 8,620.15% and a negative return on equity of 113.65%. The company had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.10 million. On average, research analysts predict that VYNE Therapeutics Inc. will post -5.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On VYNE Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC boosted its position in VYNE Therapeutics by 145.6% during the 4th quarter. Millennium Management LLC now owns 488,012 shares of the company’s stock valued at $73,000 after purchasing an additional 289,298 shares during the period. Cetera Advisor Networks LLC bought a new position in shares of VYNE Therapeutics in the second quarter valued at $45,000. Beacon Pointe Advisors LLC acquired a new stake in shares of VYNE Therapeutics during the 1st quarter valued at $49,000. Mackenzie Financial Corp acquired a new position in shares of VYNE Therapeutics in the 1st quarter worth $42,000. Finally, Renaissance Technologies LLC grew its holdings in shares of VYNE Therapeutics by 6.7% in the 1st quarter. Renaissance Technologies LLC now owns 965,098 shares of the company’s stock worth $627,000 after acquiring an additional 60,567 shares during the last quarter. Hedge funds and other institutional investors own 12.15% of the company’s stock.

About VYNE Therapeutics

(Get Free Report)

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.

Featured Articles

Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.